The Effect of First Dose of Tamsulosin on Flow Rate and Its Predictive Ability on the Improvement of LUTS in Men with BPH in the Mid-term

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2013 Jan 8

PMID 23292598

Citations 6

Authors

Yigit Akin

Hakan Gulmez

Murat Ucar

Selcuk Yucel

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate if effects of the first single dose of tamsulosin 0.4 mg on uroflowmetry parameters would predict treatment response at the third month.

Methods: Men over 40 years old with complaints of lower urinary tract symptoms associated with benign prostatic hyperplasia were studied with physical examination, urine and blood analysis, uroflowmetry (UFM), post-voiding residual urine volume (PVR), international prostate symptom score (IPSS), quality-of-life (QoL) index and transrectal prostate ultrasonography (TRUS), and patients with prostate cancer suspicion, past urinary surgery, urinary tract infection and neurologic diseases were excluded. UFM, PVR, IPSS, QoL were repeated at 6th hour of the first day, first month and third month of oral tamsulosin 0.4 mg treatment. All parameters were recorded as baseline, and changes in the UFM parameters, PVR, IPSS and QoL were evaluated in clinical visits.

Results: As a total, 48 men (mean 60.17 ± 1.18 years) were recruited. There was a significant increase in maximum urine flow rate (Q (max)) and average urine flow rate (Q (ave)) and decrease in PVR from baseline with the first dose of tamsulosin as well as first and third month of treatment (p < 0.05). IPSS and QoL scores significantly improved at the first month in correlation with UFM parameters. Tamsulosin treatment was effective in 33 (68.7 %) patients at the first administration and 35 (72.9 %) at the third month. Positive predictive value and negative predictive value of Q (max) change at first dose for the third month response rate were 90.9 and 66.6 %, respectively.

Conclusions: The mid-term effectiveness of tamsulosin may be predicted by changes in UFM parameters achieved with its first dose.

Citing Articles

Predictive value of the immediate effect of first dose of tamsulosin on lower urinary tract symptoms improvement in benign prostatic hyperplasia patients.

Moussa A, Ibrahim R, Eladawy M, Ragheb A, El-Dessoukey A, Abdelbary A Urol Ann. 2019; 11(3):294-297.

PMID: 31413509 PMC: 6676853. DOI: 10.4103/UA.UA_57_18.

Evaluation of apoptosis indexes in currently used oral alpha-blockers in prostate: a pilot study.

Demir M, Akin Y, Terim K, Gulum M, Buyukfirat E, Ciftci H Int Braz J Urol. 2018; 44(3):600-607.

PMID: 29617082 PMC: 5996798. DOI: 10.1590/S1677-5538.IBJU.2017.0668.

Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study.

Lee K, Yoo T, Liao L, Wang J, Chuang Y, Liu S BMC Urol. 2017; 17(1):108.

PMID: 29162085 PMC: 5698954. DOI: 10.1186/s12894-017-0294-3.

Recent research on the role of urodynamic study in the diagnosis and treatment of male lower urinary tract symptoms and urinary incontinence.

Jiang Y, Kuo H Tzu Chi Med J. 2017; 29(2):72-78.

PMID: 28757770 PMC: 5509199. DOI: 10.4103/tcmj.tcmj_19_17.

Preliminary assessment of Neck Circumference in Benign Prostatic Hyperplasia in Patients with Metabolic Syndrome.

Akin Y, Gulmez H, Ates E, Gulum M, Savas M Int Braz J Urol. 2017; 43(1):95-103.

PMID: 28124531 PMC: 5293389. DOI: 10.1590/S1677-5538.IBJU.2016.0139.

References

Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G . Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995; 288(2):201-7. DOI: 10.1016/0922-4106(95)90195-7. View

Lepor H . Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2008; 9(4):181-90. PMC: 2213889. View

Lyseng-Williamson K, Jarvis B, Wagstaff A . Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs. 2002; 62(1):135-67. DOI: 10.2165/00003495-200262010-00006. View

Buzelin J, Fonteyne E, Kontturi M, Witjes W, Khan A . Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol. 1997; 80(4):597-605. DOI: 10.1046/j.1464-410x.1997.00205.x. View

Chung J, Choi S, Kim B, Kim T, Yoo E, Il Kim C . Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia. Korean J Urol. 2011; 52(7):479-84. PMC: 3151636. DOI: 10.4111/kju.2011.52.7.479. View

Korstanje C, Krauwinkel W, van Doesum-Wolters F . Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?. Br J Clin Pharmacol. 2011; 72(2):218-25. PMC: 3162651. DOI: 10.1111/j.1365-2125.2010.03870.x. View

Wolzt M, Fabrizii V, Dorner G, Zanaschka G, Leufkens P, Krauwinkel W . Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study. Eur J Clin Pharmacol. 1998; 54(4):367-73. DOI: 10.1007/s002280050477. View

Chapple C . A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. Rev Urol. 2006; 7 Suppl 4:S22-30. PMC: 1477612. View

Michel M, Buscher R, Kerker J, Kraneis H, Erdbrugger W, Brodde O . Alpha 1-adrenoceptor subtype affinities of drugs for the treatment of prostatic hypertrophy. Evidence for heterogeneity of chloroethylclonidine-resistant rat renal alpha 1-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol. 1993; 348(4):385-95. DOI: 10.1007/BF00171338. View

10.

Soeishi Y, Matsushima H, Watanabe T, Higuchi S, Cornelissen K, Ward J . Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica. 1996; 26(6):637-45. DOI: 10.3109/00498259609046739. View

11.

Park C, Chang H, Oh B, Kim H, Sul C, Chung S . Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study. Clin Drug Investig. 2007; 24(1):41-7. DOI: 10.2165/00044011-200424010-00005. View

12.

Djavan B, Chapple C, Milani S, Marberger M . State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004; 64(6):1081-8. DOI: 10.1016/j.urology.2004.07.031. View

13.

Chapple C . Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade. Br J Urol. 1998; 81 Suppl 1:34-47; discussion 64-6. DOI: 10.1046/j.1464-410x.1998.0810s1034.x. View

14.

Shrivastava A, Gupta V . Various treatment options for benign prostatic hyperplasia: A current update. J Midlife Health. 2012; 3(1):10-9. PMC: 3425142. DOI: 10.4103/0976-7800.98811. View

15.

Chen Y, Zhang X, Hu X, Deng Y, Chen J, Li S . The potential role of a self-management intervention for benign prostate hyperplasia. Urology. 2012; 79(6):1385-8. DOI: 10.1016/j.urology.2011.11.091. View

16.

Kang S, Park C, Kim D, Park J, Hong S, Chung B . Long-term outcome of tamsulosin for patients with lower urinary tract symptoms according to the treatment response defined by lower urinary tract symptom outcomes score. Int J Clin Pract. 2011; 65(6):691-7. DOI: 10.1111/j.1742-1241.2011.02667.x. View

17.

Schwinn D . The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 2001; 88 Suppl 2:27-34; discussion 49-50. DOI: 10.1046/j.1464-410x.2001.00116.x. View

18.

Narayan P, Lepor H . Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 2001; 57(3):466-70. DOI: 10.1016/s0090-4295(00)01042-6. View

19.

Michel M, Mehlburger L, Goepel M . Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 2002; 1(6):332-335. DOI: 10.1038/sj.pcan.4500267. View

20.

Chute C, Panser L, Girman C, Oesterling J, Guess H, Jacobsen S . The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993; 150(1):85-9. DOI: 10.1016/s0022-5347(17)35405-8. View